Fanhua (NASDAQ:FANH – Get Free Report) was downgraded by equities research analysts at StockNews.com from a “hold” rating to a “sell” rating in a research note issued to investors on Monday.
Fanhua Trading Up 2.8 %
Shares of FANH stock opened at $1.11 on Monday. Fanhua has a 1-year low of $1.04 and a 1-year high of $7.73. The company has a market capitalization of $62.94 million, a price-to-earnings ratio of 1.52 and a beta of -0.07. The stock’s fifty day simple moving average is $1.37 and its 200-day simple moving average is $2.65.
Institutional Inflows and Outflows
A hedge fund recently raised its stake in Fanhua stock. Dimensional Fund Advisors LP raised its position in Fanhua Inc. (NASDAQ:FANH – Free Report) by 11.6% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 466,320 shares of the financial services provider’s stock after purchasing an additional 48,383 shares during the quarter. Dimensional Fund Advisors LP owned approximately 0.82% of Fanhua worth $930,000 at the end of the most recent quarter. 26.72% of the stock is currently owned by institutional investors and hedge funds.
About Fanhua
Fanhua Inc, together with its subsidiary, distributes insurance products in China. It operates through two segments, Insurance Agency and Claims Adjusting. The Insurance Agency segment provides property and casualty insurance products that primarily include individual accident, travel, homeowner, and indemnity medical insurance products; and life insurance products, such as individual health, individual whole life, individual term life, individual endowment life, and individual annuity, as well as participating insurance products.
See Also
- Five stocks we like better than Fanhua
- ESG Stocks, What Investors Should Know
- Biohaven Stock Soars on Drug Trial Results: Time to Jump In?
- Insider Trades May Not Tell You What You Think
- Is AMD a Legitimate Threat to NVIDIA? What Investors Should Watch
- The How and Why of Investing in Gold Stocks
- Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
Receive News & Ratings for Fanhua Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fanhua and related companies with MarketBeat.com's FREE daily email newsletter.